Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.

INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number...

Полное описание

Библиографические подробности
Главные авторы:	Mitchell, R, Trück, J, Pollard, A
Формат:	Journal article
Язык:	English
Опубликовано:	2013

Схожие документы

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
по: Trück, J, и др.
Опубликовано: (2016)

Differences in immunization site pain in toddlers vaccinated with either the 10- or the 13-valent pneumococcal conjugate vaccine
по: Trück, J, и др.
Опубликовано: (2018)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
по: V. K. Tatochenko, и др.
Опубликовано: (2012-03-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
по: James T. Peterson, и др.
Опубликовано: (2019-03-01)

13-valent pneumococcal conjugate vaccine in Africa
по: Robert Cohen, и др.
Опубликовано: (2017-03-01)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
по: Susanna Esposito, и др.
Опубликовано: (2015-01-01)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
по: Irina Kislaya, и др.
Опубликовано: (2019-01-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
по: Kristiana Alexandrova Nikolova, и др.
Опубликовано: (2021-10-01)

Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
по: L A Shpagina, и др.
Опубликовано: (2018-11-01)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
по: Johnna Perdrizet, и др.
Опубликовано: (2021-04-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
по: Beate Schmoele-Thoma, и др.
Опубликовано: (2019-03-01)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
по: S. M. Kharit, и др.
Опубликовано: (2016-12-01)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
по: Corinne Levy, и др.
Опубликовано: (2021-08-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
по: Filippo Ansaldi, и др.
Опубликовано: (2020-01-01)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
по: Paul Turner, и др.
Опубликовано: (2015-11-01)

Pneumococcal serotypes causing pneumonia in the 13 valent pneumococcal conjugate vaccine era in Australian children
по: R. Strachan, и др.
Опубликовано: (2020-12-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
по: Hye-Young Kim, и др.
Опубликовано: (2021-03-01)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
по: Miguel Gouveia, и др.
Опубликовано: (2019-04-01)

Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England.
по: Jo Southern, и др.
Опубликовано: (2018-01-01)

Experience with 13-valent conjugated pneumococcal vaccine in HIV-infected patients
по: A. V. Zhestkov, и др.
Опубликовано: (2020-12-01)

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
по: Rodgers, G, и др.
Опубликовано: (2013)

Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil
по: Indianara Maria Grando, и др.
Опубликовано: (2015-02-01)

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
по: Albert Jan van Hoek, и др.
Опубликовано: (2016-01-01)

Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules
по: Hong-Yi Lee, и др.
Опубликовано: (2018-04-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.
по: Sweta M Patel, и др.
Опубликовано: (2022-01-01)

Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
по: Kristiana Alexandrova Nikolova, и др.
Опубликовано: (2024-02-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
по: Sweta M. Patel, и др.
Опубликовано: (2022-01-01)

Failures of 13-Valent Conjugated Pneumococcal Vaccine in Age-Appropriately Vaccinated Children 2–59 Months of Age, Spain
по: Sergi Hernández, и др.
Опубликовано: (2020-06-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
по: Sabine Haggenburg, и др.
Опубликовано: (2023-07-01)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
по: Matthew Wasserman, и др.
Опубликовано: (2019-03-01)

Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy.
по: Romina Camilli, и др.
Опубликовано: (2013-01-01)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
по: Matt Wasserman, и др.
Опубликовано: (2021-06-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
по: Hannah M. Garcia Garrido, и др.
Опубликовано: (2022-05-01)

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children
по: Ayieko, P, и др.
Опубликовано: (2013)

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
по: Philip Ayieko, и др.
Опубликовано: (2013-01-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
по: Earnshaw Stephanie R, и др.
Опубликовано: (2012-04-01)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
по: Min-Joo Choi, и др.
Опубликовано: (2018-08-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
по: Thundon Ngamprasertchai, и др.
Опубликовано: (2023-06-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
по: N. L. Chernaya, и др.
Опубликовано: (2012-02-01)

Immunogenicity and Safety of 13-valent Conjugated Pneumococcal Vaccine in Patients with Rheumatoid Arthritis
по: B. T. Batozhargalova, и др.
Опубликовано: (2024-03-01)